The Atrial project is dedicated to the pursuit of the clinical development of a promising novel therapeutic (GBC-A1) in atrial fibrillation (AF), the most common serious abnormal heart rhythm, which affects 2 to 3% of the population in Europe and North America.
GBC-Atrial has obtained an exclusive world-wide license relating to the clinical development of this asset. Furthermore, GBC-A1 has already been in clinical development in another indication up to phase IIa (proof-of-concept), and displayed a remarkable tolerability and safety profile. GBC-A1 was recently the subject of a phase Ia clinical trial financed by GBC-Atrial to determine the suitability of this molecule in a cardiac setting: not only was GBC-A1 was very well tolerated, but it also displayed the first signs of efficacy in a cardiac setting.
The pursuit of this development plan involves a more extended single ascending dose study, followed by a multiple ascending dose, a small food-effect study, and an cardiac electrophysiology study to fully de-risk the subsequent phase II studies. Two phase II studies are planned, a proof-of-concept study, and a full-blown phase IIb study on atrial fibrillation patients.
GBC-Atrial is looking for partners to finance the remainder of the phase I and phase II parts of the clinical development pipeline. The partners would enter into the ownership of the GBC-Atrial SA at very favorable terms. We are also open to other co-development possibilities with pharmaceutical company partners.